Assay selection framework
How to weigh critical parameters including specificity, precision, accuracy, throughput, and platform compatibility.
Join QuTEM and Eli Lilly on December 2, 2026, for an in-depth session on optimizing AAV gene therapy analytical methods.
AAV-based gene therapy samples are inherently heterogeneous, often composed of capsid monomers, aggregates, and fragment species. Accurately tracking and characterizing these size-variant populations is crucial for delivering a consistent, high-quality product to patients and deeply understanding aggregation assay readouts.
QuTEM is thrilled to announce a joint educational webinar featuring Rickard Nordström, Chief Operating Officer at QuTEM, and Margaret Butko, Ph.D., Senior Advisor of CMC Assay Development at Eli Lilly and Company.
This session will explore a practical framework for selecting the right aggregation assays based on the specific context — whether for product release, in-process testing, characterization, or early-stage discovery.
Whether you are navigating early discovery or post-commercialization testing, this session will provide actionable insights into characterizing complex AAV products.
